1. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
2. Cabozantinib exposure‐response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first‐line advanced renal cell carcinoma;Tran BD;Cancer Chemother Pharmacol,2023
3. Center for Drug Evaluation and Research US Food and Drug Administration.Clinical Pharmacology and Biopharmaceutics Review: Application Number 212306Orig1s000; selinexor [Internet].2019[cited 2023 May 1].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf
4. Center for Drug Evaluation and Research US Food and Drug Administration.Clinical Pharmacology and Biopharmaceutics Review: Application Number 761040Orig1s000; Inotuzumab Ozogamicin [Internet].2016[cited 2023 May 1].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761040Orig1s000MultidisciplineR.pdf
5. BaronKT GillespieB MargossianC et al.mrgsolve: Simulate from ODE‐Based Models [Internet]. Metrum Research Group2021https://cran.r‐project.org/package=mrgsolve